Literature DB >> 7516361

Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study.

R Solà1, M C Vila, M Andreu, M I Oliver, S Coll, J Gana, S Ledesma, P Ginès, W Jiménez, V Arroyo.   

Abstract

The aim of the current study was to compare total paracentesis associated with dextran-40 infusion with diuretics in the treatment of tense ascites in patients with cirrhosis. Eighty patients were randomly allocated to two groups: 40 patients were treated with paracentesis plus dextran-40 infusion (8 g per liter of ascitic fluid removed), and 40 patients with diuretics. After treatment patients were discharged with diuretics, and patients developing tense ascites during follow up (54 +/- 4 weeks) were treated according to their initial schedule. Paracentesis was more effective than diuretics in mobilizing the ascitic fluid. The incidence of complications was significantly higher (p < 0.05) in the diuretic group (38%) than in the paracentesis group (15%). This difference was mainly due to a higher incidence of hepatic encephalopathy in the former group (30% vs. 2.5%). A significantly higher incidence of hepatic encephalopathy was also observed in the diuretic group during the follow-up readmissions for ascites recurrence. There were no significant differences between the two treatment groups in the probability of survival after inclusion. Plasma renin activity and plasma aldosterone concentration measured before and 2 and 6 days after paracentesis in 20 randomly selected patients increased significantly (p < 0.05) (baseline values: 5.3 +/- 1.4 ng.ml-1.h-1 and 63 +/- 21 ng/dl; 48 h after paracentesis: 11.7 +/- 3.9 ng.ml-1.h-1 and 99 +/- 31 ng/dl; 6 days after paracentesis: 10.9 +/- 3 ng.ml-1.h-1 and 110 +/- 27 ng/dl).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516361     DOI: 10.1016/s0168-8278(05)80070-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

1.  Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites.

Authors:  G Nasr; A Hassan; S Ahmed; A Serwah
Journal:  J Cardiovasc Dis Res       Date:  2010-07

2.  Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives: Chapter 5 Human Albumin - Revised.

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-03       Impact factor: 3.747

Review 3.  Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Authors:  Hiroshi Fukui; Hidetsugu Saito; Yoshiyuki Ueno; Hirofumi Uto; Katsutoshi Obara; Isao Sakaida; Akitaka Shibuya; Masataka Seike; Sumiko Nagoshi; Makoto Segawa; Hirohito Tsubouchi; Hisataka Moriwaki; Akinobu Kato; Etsuko Hashimoto; Kojiro Michitaka; Toshikazu Murawaki; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-05-31       Impact factor: 7.527

4.  Diagnosis and therapy of ascites in liver cirrhosis.

Authors:  Erwin Biecker
Journal:  World J Gastroenterol       Date:  2011-03-14       Impact factor: 5.742

Review 5.  Management of cirrhotic ascites.

Authors:  Julie Steen Pedersen; Flemming Bendtsen; Søren Møller
Journal:  Ther Adv Chronic Dis       Date:  2015-05       Impact factor: 5.091

6.  Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Amine Benmassaoud; Suzanne C Freeman; Davide Roccarina; Maria Corina Plaz Torres; Alex J Sutton; Nicola J Cooper; Laura Iogna Prat; Maxine Cowlin; Elisabeth Jane Milne; Neil Hawkins; Brian R Davidson; Chavdar S Pavlov; Douglas Thorburn; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16

7.  AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis.

Authors:  Paolo Caraceni; Paolo Angeli; Daniele Prati; Mauro Bernardi; Giancarlo M Liumbruno; Francesco Bennardello; Pierluigi Piccoli; Claudio Velati
Journal:  Blood Transfus       Date:  2016-01       Impact factor: 3.443

Review 8.  TIPS versus paracentesis for cirrhotic patients with refractory ascites.

Authors:  S Saab; J M Nieto; S K Lewis; B A Runyon
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

9.  Clinical Profile and Complications of Paracentesis in Refractory Ascites Patients With Cirrhosis.

Authors:  Sreenivasa Rao Sudulagunta; Mahesh Babu Sodalagunta; Shiva Kumar Bangalore Raja; Hadi Khorram; Mona Sepehrar; Zahra Noroozpour
Journal:  Gastroenterology Res       Date:  2015-07-22

10.  Long-term administration of Tolvaptan to patients with decompensated cirrhosis.

Authors:  Kengo Kanayama; Tetsuhiro Chiba; Kazufumi Kobayashi; Keisuke Koroki; Susumu Maruta; Hiroaki Kanzaki; Yuko Kusakabe; Tomoko Saito; Soichiro Kiyono; Masato Nakamura; Sadahisa Ogasawara; Eiichiro Suzuki; Yoshihiko Ooka; Shingo Nakamoto; Shin Yasui; Tatsuo Kanda; Hitoshi Maruyama; Jun Kato; Naoya Kato
Journal:  Int J Med Sci       Date:  2020-03-15       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.